만성 염증성 탈수초성 다발신경병증(CIDP) 시장 : 치료법, 환자 연령, 질환 중증도, 최종 사용자, 유통 채널별 - 세계 예측(2026-2032년)

The Chronic Inflammatory Demyelinating Polyneuropathy Market was valued at USD 2.64 billion in 2025 and is projected to grow to USD 2.80 billion in 2026, with a CAGR of 5.97%, reaching USD 3.96 billion by 2032.

Concise framing of clinical complexity, treatment pathways, and strategic priorities to orient stakeholders toward informed decisions across care, research, and commercialization

Chronic inflammatory demyelinating polyneuropathy presents distinct clinical, diagnostic, and therapeutic complexities that demand integrated analysis for strategic decision making. This executive summary synthesizes current understanding of disease biology, care pathways, therapeutic modalities, and the commercial environment to equip clinicians, payers, and industry stakeholders with a concise yet comprehensive briefing. It addresses how evolving diagnostic criteria, advances in immunotherapy, and shifts in care delivery intersect to influence patient journeys and service utilization.

By focusing on evidence-based treatment practices and operational realities across settings of care, the narrative connects clinical endpoints with real-world considerations such as treatment tolerability, infusion infrastructure, and the capacity of specialty clinics and home care services. Moreover, the introduction frames emerging clinical trial trends and regulatory approaches that are reshaping the competitive landscape. Ultimately, this section sets the stage for a deeper exploration of transformative shifts, tariff implications, segmentation intelligence, regional dynamics, and actionable recommendations crafted for executives and clinical leaders tasked with navigating a complex, rapidly changing field.

How diagnostic advances, treatment innovation, and care delivery redesign are converging to redefine therapeutic approaches and value assessment in patient management

The landscape for managing chronic inflammatory demyelinating polyneuropathy is undergoing transformative shifts driven by technological maturation, regulatory refinement, and evolving patient expectations. Novel diagnostics and biomarker research are improving case ascertainment and prognostic stratification, which in turn support more targeted therapeutic strategies. Concurrently, advances in the formulation and delivery of immunoglobulin therapies, alongside growing experience with monoclonal antibodies and other immunomodulatory agents, are expanding clinician options and prompting reassessment of long-term management protocols.

At the same time, health systems are adjusting care delivery models to emphasize outpatient and home-based administration where clinically appropriate. This shift is facilitated by advancements in subcutaneous immunoglobulin formulations and remote monitoring technologies, which reduce reliance on inpatient infusion centers and enhance patient convenience. Transitional dynamics also include payer scrutiny around long-term therapy value, leading to more rigorous outcomes measurement and utilization management. Collectively, these forces are accelerating a move toward personalized, value-oriented care that recognizes both clinical efficacy and system sustainability.

Assessment of tariff policy effects on supply chains, manufacturing strategies, and treatment availability with implications for procurement and clinical decision making

Policy developments in trade and tariffs can exert significant influence on manufacturing economics, supply chain resilience, and the cost structure of therapies used in chronic inflammatory demyelinating polyneuropathy care. Changes to import duties or regulatory requirements for raw materials and finished biologics may increase upstream sourcing complexity, prompting manufacturers to reassess supplier networks and inventory strategies. In parallel, tariffs can shift the geographic economics of production, encouraging relocation of manufacturing nodes or the adoption of dual-sourcing arrangements to mitigate exposure to trade disruptions.

These dynamics can cascade into downstream stakeholders: hospital pharmacies, specialty clinics, and distribution channels may face altered procurement lead times or pricing pressures that necessitate adjustments in contracting and inventory management. Clinicians and health systems may experience variability in product availability, which could influence therapeutic choices between intravenous and subcutaneous formulations where multiple options exist. Consequently, strategic planning must incorporate scenario analysis of tariff impacts on supply continuity, cost of goods, and the operational feasibility of home care versus facility-based administration, while also engaging with payers to align reimbursement models with emerging cost structures.

In-depth segmentation analysis linking therapy characteristics, care settings, distribution pathways, age cohorts, and severity gradations to clinical and operational decision frameworks

Segment-specific analysis reveals differentiated operational and clinical imperatives across treatment modalities, care settings, distribution mechanisms, patient age groups, and disease severity categories. When examined by treatment modality, the therapeutic mix spans corticosteroids, immunosuppressants - including azathioprine, cyclophosphamide, mycophenolate mofetil, and rituximab - intravenous immunoglobulin, plasma exchange, and subcutaneous immunoglobulin, each with distinct administration requirements, monitoring needs, and safety profiles that influence site selection and resource allocation. In this context, immunosuppressant subtypes demand specialized monitoring protocols and patient counseling that can shape utilization patterns in specialty clinics compared with broader hospital settings.

End-user segmentation highlights the operational tradeoffs between home care, hospitals, and specialty clinics. Home care models prioritize patient education, device compatibility, and remote monitoring, while hospitals underscore infusion capacity and acute management capabilities. Specialty clinics often serve as hubs for diagnostic clarification and initiation of long-term immunotherapy. Distribution channel differentiation across hospital pharmacy, online pharmacy, and retail pharmacy affects dispensing practices, cold chain stewardship, and patient access. Patient age segmentation into adult, geriatric, and pediatric populations underscores differing safety considerations, dosing strategies, and caregiver support needs that must be integrated into treatment planning. Disease severity segmentation - mild, moderate, and severe - further informs therapeutic sequencing, frequency of interventions, and intensity of monitoring, creating decision pathways that intersect with payer authorization and care coordination requirements.

Comparative regional dynamics and strategic considerations across major global territories shaping access, reimbursement, and delivery of therapeutic options

Regional dynamics shape clinical practice patterns, regulatory environments, reimbursement frameworks, and supply logistics across the Americas, Europe, Middle East & Africa, and Asia-Pacific markets. In the Americas, evolving payer models and robust specialty care networks support a focus on outpatient infusion services and home administration where clinically appropriate, while regulatory clarity around biologics and immunotherapies encourages innovation in delivery platforms. Conversely, certain jurisdictions in Europe, the Middle East, and Africa exhibit heterogeneity in access and reimbursement, prompting localized strategies that account for national formularies, centralized procurement, and regional manufacturing partnerships.

In the Asia-Pacific region, rapid growth in healthcare infrastructure and an expanding base of specialist clinicians are creating opportunities for broader access to advanced therapies, though variability in regulatory pathways and local manufacturing capacity remains a factor. Across these regions, transitions toward value-based procurement and a greater emphasis on real-world evidence are influencing formulary decisions and clinical guidelines. Therefore, market entrants and established suppliers must calibrate commercialization strategies to local regulatory, payer, and delivery realities, while also coordinating cross-regional supply chain and medical affairs efforts to ensure consistent standards of care.

Competitive and collaborative imperatives for manufacturers and service providers to align clinical evidence, supply logistics, and patient support for sustainable growth

Competitive intelligence indicates that a diverse set of organizations - from biopharmaceutical manufacturers producing immunoglobulin formulations to specialty service providers delivering plasma exchange and home infusion capabilities - are active in this therapeutic area. Firms that combine clinical development expertise with robust manufacturing and distribution infrastructures are better positioned to meet the complex cold chain and quality control demands inherent to biologic therapies. In addition, entities that invest in patient support programs, training for home care nurses, and digital adherence tools strengthen their value proposition to payers and providers.

Partnerships between pharmaceutical companies and logistics providers, as well as collaborations with academic centers for post-marketing evidence generation, are becoming more common. These alliances support lifecycle management strategies and help build the real-world datasets that payers increasingly require. Service providers that offer scalable infusion capacity and streamlined prior authorization support gain traction with clinicians seeking to minimize administrative burden. Overall, organizations that align clinical evidence generation with operational excellence and stakeholder engagement are likely to sustain competitive advantage as treatment paradigms evolve.

Practical strategic measures for executives to enhance evidence generation, fortify supply chains, and advance care delivery to sustain clinical and commercial success

Industry leaders should pursue a multipronged strategy that integrates clinical evidence development, supply chain resilience, and stakeholder engagement to maximize therapeutic impact and operational sustainability. First, prioritize generation of robust real-world evidence and targeted clinical studies that clarify long-term outcomes, comparative effectiveness across modalities, and cost-utility measures that resonate with payers. Second, strengthen supply chain resilience by diversifying sourcing of critical raw materials, establishing regional manufacturing or fill-finish capabilities, and negotiating flexible logistics arrangements to mitigate tariff and trade risks.

Third, invest in care delivery innovations that expand safe home administration and support specialty clinics through training, telehealth integration, and digital monitoring tools to improve adherence and reduce total cost of care. Fourth, engage proactively with payers and policy makers to align reimbursement pathways with clinical value, leveraging outcomes data and patient-reported measures. Finally, cultivate cross-sector partnerships - including with academic institutions and patient advocacy groups - to accelerate guideline adoption, improve patient education, and ensure equitable access across age cohorts and severity profiles. Together, these actions create a resilient commercial model grounded in clinical credibility and operational adaptability.

Transparent, multi-source research approach combining expert interviews, systematic literature review, and iterative validation to produce actionable clinical and operational insights

The research methodology underpinning this analysis combines qualitative expert engagement, rigorous review of primary literature, and structured synthesis of operational and regulatory developments. Primary inputs included consultations with clinical specialists, pharmacy leaders, and health system administrators to capture frontline perspectives on treatment selection, infusion capacity, and patient management. These interviews were complemented by a systematic review of peer-reviewed clinical studies, regulatory guidance, and professional society recommendations to ensure that therapeutic and diagnostic trends are grounded in validated evidence.

To ensure reliability, findings were triangulated across multiple sources and validated through iterative expert review. Attention was given to distinguishing established clinical practice from emerging experimental approaches, and to identifying gaps in evidence where further research is warranted. Limitations are acknowledged: regional heterogeneity in clinical guidelines and the variable quality of real-world datasets can constrain the generalizability of certain operational inferences. Nonetheless, the methodology emphasizes transparency, reproducibility, and the practical applicability of insights for decision-makers in clinical, commercial, and policy roles.

Synthesis of clinical trends, operational challenges, and strategic levers that together define the pathway to improved patient outcomes and sustainable care delivery

This executive synthesis delivers a cohesive view of the clinical, operational, and strategic forces shaping care for chronic inflammatory demyelinating polyneuropathy. It underscores a shift toward personalized immunomodulatory strategies, increasing emphasis on home and outpatient delivery models, and the rising importance of real-world evidence to support payer engagement. The analysis also highlights supply chain considerations and policy-driven pressures that can influence availability and selection of therapies, reinforcing the need for proactive contingency planning and stakeholder alignment.

In closing, effective responses require coordinated action across evidence generation, supply operations, and payer engagement to ensure that patients receive timely, appropriate care while health systems manage cost and capacity. Stakeholders who integrate clinical insight with pragmatic operational strategies will be better positioned to navigate uncertainty and to translate scientific advances into improved outcomes for patients living with this chronic neurologic condition.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Treatment Modality

• 8.1. Corticosteroids
• 8.2. Immunosuppressants
  • 8.2.1. Azathioprine
  • 8.2.2. Cyclophosphamide
  • 8.2.3. Mycophenolate Mofetil
  • 8.2.4. Rituximab
• 8.3. Intravenous Immunoglobulin
• 8.4. Plasma Exchange
• 8.5. Subcutaneous Immunoglobulin

9. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Patient Age

• 9.1. Adult
• 9.2. Geriatric
• 9.3. Pediatric

10. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Disease Severity

• 10.1. Mild
• 10.2. Moderate
• 10.3. Severe

11. Chronic Inflammatory Demyelinating Polyneuropathy Market, by End User

• 11.1. Home Care
• 11.2. Hospitals
• 11.3. Specialty Clinics

12. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Distribution Channel

• 12.1. Hospital Pharmacy
• 12.2. Online Pharmacy
• 12.3. Retail Pharmacy

13. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. United States Chronic Inflammatory Demyelinating Polyneuropathy Market

17. China Chronic Inflammatory Demyelinating Polyneuropathy Market

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025
• 18.5. Avalon Pharma Pvt Ltd.
• 18.6. Baxter International, Inc.
• 18.7. Biotest AG
• 18.8. CSL Limited
• 18.9. F. Hoffmann-La Roche Ltd.
• 18.10. Green Cross Corporation
• 18.11. Grifols, S.A.
• 18.12. Johnson & Johnson Services, Inc.
• 18.13. Kedrion Biopharma
• 18.14. Lee BioSolutions
• 18.15. Merck & Co., Inc.
• 18.16. Novartis AG
• 18.17. Octapharma AG
• 18.18. Pfizer Inc.
• 18.19. Sanofi SA
• 18.20. Takeda Pharmaceutical Company Limited
• 18.21. Teva Pharmaceutical Industries Ltd.
• 18.22. UCB S.A.
• 18.23. Viatris Inc.
• 18.24. Zai Lab Limited